Atai Stock: A $660 Million Loss — and $530 Million of It Never Left the Bank Account

The drugs this company is building work on the principle that what you perceive depends on the setting you are in. Researchers call it "set and setting": the same molecule can produce relief or panic depending on the room, the music and the person sitting with you. Here is the uncomfortable part — your reading of a balance sheet works exactly the same way. Put the number "$660 million loss" in a headline, and your nervous system files the company under catastrophe before your eyes reach the second line. Put the phrase "funded into 2029" in an annual report, and the same nervous system relaxes. Both reactions are the setting talking, not the number. AtaiBeckley Inc. (Nasdaq: ATAI) is an unusually clean laboratory for this effect, because its two most important figures mislead in opposite directions — one is far less frightening than it looks, the other far less comforting. So let us make a deal: we drop the framing and read only what the company itself filed with the U.S. securities regulator, the SEC — and a filing to the SEC is honest under penalty of law. Our material: the annual report (10-K) for 2025 and the quarterly report (10-Q) as of March 31, 2026. At the end you will not get a verdict from us. You will get the findings, and the setting will be yours to choose.

What AtaiBeckley actually does — nasal sprays for the depression nobody can treat

Start with the problem, because it is real and it is enormous. Depression is treated today mainly with SSRIs and SNRIs — the familiar antidepressants. They work well for many people. For a large minority they do not: by the company's account, drawing on the clinical literature, roughly 65 percent of patients do not achieve remission after up to four antidepressant trials. Of an estimated 300 million people with depression worldwide, about half are considered treatment-resistant, meaning at least two different antidepressants have failed them. That is the gap AtaiBeckley aims at, and the tool it has chosen is the one class of compounds mainstream psychiatry spent fifty years refusing to touch: psychedelics. The pitch is not "a better SSRI". It is a different mechanism — a single supervised dose that acts within a day and, in early trials, holds for weeks or months, rather than a pill taken every morning for years.

The pipeline is four names, and it is worth knowing which is which. BPL-003 is the lead: a dry-powder nasal spray of mebufotenin benzoate — the compound better known as 5-MeO-DMT — for treatment-resistant depression. VLS-01 is a buccal film (a strip that dissolves against the inside of your cheek) of DMT for the same indication. EMP-01 is an oral form of R-MDMA for social anxiety disorder. And a discovery program is hunting for molecules with the therapeutic effect but without the hallucinations — which, if it ever works, would remove the single biggest obstacle to prescribing these drugs at scale. Translated into everyday terms: the company is trying to turn substances that currently require a clinic, a supervisor and a long afternoon into something closer to a treatment you can schedule. The early BPL-003 data is why anyone cares: in Part 1 of the Phase 2a study a single 10 mg dose produced a response — a halving of the depression score — in 55 percent of patients the day after dosing, still holding at weeks 4 and 12; patients were generally ready for discharge in under two hours, and no serious adverse events were reported. Part 2, in patients staying on their SSRIs, showed a mean 18-point drop on the depression scale the day after dosing and 18 points still at three months. Small studies — 12 patients dosed in each — but the direction is what got the FDA's attention. After an End-of-Phase 2 meeting in February 2026, the company said it was on track to begin the Phase 3 program in the second quarter of 2026: two pivotal trials, each a 12-week core study plus a 52-week extension.

The corporate history matters more than usual here, because it explains half the numbers below. The company as it exists today was assembled in November 2025, when atai Life Sciences N.V. combined with Beckley Psytech Limited — the British company that originated BPL-003. Then, on December 30, 2025, it moved house: the Dutch company merged into a Luxembourg entity, which converted the same day into a Delaware corporation called AtaiBeckley Inc. That is why the shares are now plain U.S. common stock with a $0.01 par value, why the company files 10-Ks rather than the 20-F forms of a foreign issuer — and why, as we will see, its own SEC archive is split in two. Which brings us to the central tension of this analysis, and it runs through every chapter: AtaiBeckley's headline numbers mislead in both directions — the terrifying $660 million loss is mostly an accounting entry that never cost a cent, while the reassuring promise of funding "into 2029" rests on a burn rate that is climbing just as the most expensive trials in the company's history begin.

Where the ticker comes from — and why our fundamental scanner does not know it

Honesty first: ATAI appears in none of our fundamental stock scanners, and it has no row in our company database. That is not a verdict, it is systematics — and in this case the systematics are unusually easy to explain. Our in-house stock scanner works through a universe of U.S. companies; until December 30, 2025, AtaiBeckley was a Dutch naamloze vennootschap, and it has been a Delaware corporation for barely six months at the time of writing. It fell through the grid, and the grid has not caught up. The ticker landed on our desk through a different tool: our Reddit hype scanner, which reads daily which small and mid caps are suddenly being talked about in the U.S. stock forums (data basis: ApeWisdom). As of July 16, 2026 it counted 12 mentions in 24 hours — a quiet hum rather than a drumbeat, but psychedelics stocks have a way of turning quiet hums into stories. For this analysis the consequence is concrete: no Piotroski score, no Altman Z, no scanner grade to lean on. There is no shortcut here — only the original documents. All the more reason to read them properly, which is what the rest of this piece does.

The numbers over the years — honestly appraised

Let us start with the number everyone quotes, and then take it apart. For fiscal year 2025 (ended December 31, 2025), AtaiBeckley reported a net loss attributable to stockholders of $660.0 million, against $149.3 million in 2024 — a loss more than four times larger, at a company whose entire market value is around $1.83 billion. Read as a headline, that is a company incinerating a third of itself in a year. Read in the income statement, it is something quite different. Of $648.2 million in total operating expenses, $530.0 million is a single line: "acquisition of in-process research and development" — the accounting treatment of the Beckley Psytech and Psilera deals. When a company buys assets rather than a business, the research it has bought must be expensed immediately and in full. No cash leaves the building. It is a bookkeeping entry recording that AtaiBeckley paid for Beckley's science with its own shares. Strip it out, and the operating company underneath looks like this: research and development of $53.1 million (2024: $55.5 million — down 4 percent) and general and administrative expenses of $65.1 million (2024: $47.5 million — up 37 percent, largely the professional fees for the combination and the move to Delaware). And the number that settles the argument, because cash cannot be booked into existence: net cash used in operating activities was $102.7 million in 2025 (2024: $82.4 million). That is the real burn. Remember the mechanism: a charge is not a payment — but a payment is always a payment.

So much for the reassuring direction. Now the other one. The first quarter of 2026 shows what happens when the accounting noise stops and the actual science starts costing money: research and development rose 54 percent to $17.4 million (prior-year quarter: $11.3 million) and administration 36 percent to $14.4 million, for total operating expenses of $31.9 million — up 45 percent. Inside the R&D line you can watch the pipeline wake up: BPL-003 consumed $2.5 million against nothing a year earlier, VLS-01 $5.5 million against $2.3 million, EMP-01 $1.7 million against $0.4 million. The quarter's net loss attributable to stockholders was $29.8 million (prior-year quarter: $26.4 million) — an honest, boring, cash-shaped loss with no $530 million theatrics in it. And revenue went the wrong way: $1.0 million, down 39 percent. Which raises the question this company's income statement never quite answers on its own.

What the filings say — the uncomfortable truths

Uncomfortable truth no. 1: there is no product business — and the "revenue" is not from the drugs

AtaiBeckley reported $4.1 million of total revenue in 2025. It is tempting to read that as a small drug business starting to turn. It is not. $0.2 million was licensing income, and $3.9 million came from research and development services performed by Nualtis — a subsidiary the group ended up owning in October 2024 when the secured debt it held in a company called IntelGenx was discharged in exchange for it. In other words: essentially all of the revenue comes from a lab-services business acquired through a bankruptcy workout, not from a single molecule in the pipeline. The annual report does not dress this up:

"We are a clinical stage biotechnology company with a limited operating history. We anticipate that we will incur significant losses for the foreseeable future and have incurred losses in each year since our inception. Our net loss attributable to AtaiBeckley, Inc. stockholders for the years ended December 31, 2025 and 2024 was $660.0 million and $149.3 million, respectively. We have no products that are approved for commercial sale and have not generated any commercial product revenue."

— AtaiBeckley Inc., SEC annual report 10-K 2025, Item 1A "Risk Factors"

The cumulative price of that sentence is on the balance sheet: an accumulated deficit of $1.4 billion as of March 31, 2026 — every dollar this organization and its predecessors have lost since inception, stacked up. Against it stands stockholders' equity of $198.7 million and total assets of $264.9 million. This is entirely normal for the industry, and it is exactly why the industry is dangerous: a clinical-stage biotech is a bet that the science arrives before the money runs out, and nothing else. How long that road can be — and that it sometimes ends well — is something you can watch in our analysis of Cytokinetics: twenty years of losses and negative equity, and then a record chart after the first approval. Remember the yardstick: until a regulator says yes, a pipeline is a cost, not a business.

Uncomfortable truth no. 2: the shares pay for the science — the count more than doubled in twelve months

If there is no revenue, the money has to come from somewhere, and at AtaiBeckley it comes from you. Look at the share count on the balance sheets: 167,959,752 shares issued and outstanding on December 31, 2024 — and 363,280,522 on December 31, 2025. That is plus 116 percent in one year; by May 8, 2026 it stood at 368,166,674. Four raises did it, and the annual report lists them in a single unbroken passage: a February 2025 public offering of 30.1 million shares at $2.10 (net $59.1 million), a June PIPE at $1.84 (net $28.1 million), a July PIPE at $2.19 (net $46.7 million), and an October offering of 23.7 million shares at $5.48 (net $121.7 million). Note the prices: the company sold nearly a third of itself in the low $2 range, months before the stock traded at more than double that. And it does not hedge about what this meant for the people already holding:

"As a result of this offering, our shareholders experienced significant dilution."

— AtaiBeckley Inc., SEC annual report 10-K 2025, Item 1A "Risk Factors"

Put the two numbers from the last chapter side by side and the machine becomes visible: financing activities brought in $269.5 million in 2025, and operations consumed $102.7 million. The company raised roughly two and a half times what it burned — which is prudent, and which is also the point: the fuel is not sales, it is your ownership percentage. And the tank is being refilled. On March 6, 2026 AtaiBeckley signed a new at-the-market program with Jefferies, letting it sell stock straight into the market whenever it likes; as of March 31, 2026 it had not used it. With 750.0 million shares authorized against 368.2 million outstanding, the room to keep going is roughly the size of the company again. None of this is improper — it is how clinical-stage biotech is financed, and selling shares beats selling the pipeline. But if you own this stock, know what you own: a claim that management has both the right and the stated intention to divide further. What serial dilution looks like when the story runs longer than the results is something we traced at Virgin Galactic.

Uncomfortable truth no. 3: "funded into 2029" — and a burn rate that is climbing into the most expensive year yet

Here is where the setting flips the other way. The liquidity note in the quarterly report opens under a heading that would stop most readers cold — "Liquidity and Going Concern" — and then says something considerably calmer than the heading suggests:

"The Company has incurred significant losses and negative cash flows from operations since its inception. As of March 31, 2026, the Company had cash and cash equivalents of $43.1 million and short-term securities of $166.8 million and its accumulated deficit was $1.4 billion. [...] The Company currently expects that its existing cash and cash equivalents and short-term securities as of March 31, 2026 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the unaudited condensed consolidated financial statements are issued."

— AtaiBeckley Inc., SEC quarterly report 10-Q as of March 31, 2026, Note 1 "Organization and Description of Business — Liquidity and Going Concern"

Be precise about what that does and does not say, because this is where careless bears get it wrong: the auditors and the company raise no substantial doubt about the company's ability to continue. "Liquidity and Going Concern" is the standard name for the note, not a warning inside it. There is no going-concern qualification here — which is genuinely more than several of the clinical-stage biotechs we have looked at can say. Management goes further in the MD&A, estimating that cash "will be sufficient to fund operations into 2029". Now do the arithmetic yourself, because that is the part the setting hides. Cash and short-term securities as of March 31, 2026: $209.9 million. "Into 2029" means somewhere north of two and a half years from that date. That implies an average burn of roughly $75 to $80 million a year. But the company burned $102.7 million in 2025 — and the first quarter of 2026 ran at $31.9 million of operating expenses, which annualizes to about $127 million. The runway promise therefore requires spending to fall by roughly a third, in the very years the company plans to run two pivotal Phase 3 trials with 52-week extensions — the single most expensive thing a biotech ever does. To be fair, the 10-K's version of the sentence quietly widens the base: it counts "proceeds from our public offering", "marketable securities" and "committed term loan funding" toward that 2029 date, and the company states plainly that its operating plan "has, and may continue to change". Both things can be true: no crisis is visible, and the arithmetic does not obviously close. A company that lasted into 2028 on a similar promise is our Taysha analysis. Remember the image: a runway is a division, and the company controls the number underneath it.

Uncomfortable truth no. 4: even a perfect trial does not make this drug sellable

Suppose everything works. The Phase 3 trials read out well, the FDA approves BPL-003. You would think that is the finish line. It is not — because the active ingredient is 5-MeO-DMT, and under U.S. law that currently sits in Schedule I of the Controlled Substances Act: the category defined as having no accepted medical use, which by definition may not be prescribed, marketed or sold. Approval by the FDA does not move it. A separate agency, the DEA, has to reschedule the substance through a formal rule-making process — notice, public comment, requests for hearing — and then every U.S. state has to make its own determination on top. The annual report walks through this and lands on a sentence that deserves its own line:

"Commercial marketing in the United States will also require scheduling-related legislative or administrative action. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance. [...] There can be no assurance that the DEA will make a favorable scheduling decision."

— AtaiBeckley Inc., SEC annual report 10-K 2025, Item 1A "Risk Factors"

Translate it into an everyday image: the company can win the trial, pass the exam and receive the certificate — and still need a second, separate authority to unlock the cabinet the medicine is kept in. And even a favorable outcome carries a cost: a scheduled drug means DEA registrations for every facility, quotas, security cages, inventory reconciliation and reporting obligations, all of which are permanent operating expense. Add the practical shape of the treatment itself — a supervised dose in a clinic, with staff, a room and hours of monitoring — and you can see why the discovery program hunting for non-hallucinogenic molecules is more than a science-fair project; it is the company's own hedge against its own business model. Remember the sequence: with psychedelics, FDA approval is the second-to-last gate, not the last one. How completely a clinical-stage story can hinge on a single regulator's decision is the whole subject of our Replimune analysis.

Valuation: $1.83 billion for four molecules and a trial calendar

In mid-July 2026 the market valued AtaiBeckley at roughly $1.83 billion, at a share price around $5 (data as of July 16, 2026). Almost every ratio you would normally reach for is meaningless here, and saying so is more honest than computing it anyway. A price-to-earnings ratio does not exist — there are no earnings and none are forecast; analysts model a loss of about $0.44 per share for the current year and roughly the same for next. A price-to-sales ratio technically computes to about 450 times 2025 revenue, which tells you nothing except that the denominator is a lab-services line item that has no connection to the investment case. Two anchors do carry information. First, enterprise value of roughly $1.6 billion — the market value less the net cash — which is what you are actually paying for the science, and it means about $1.6 billion is riding on four molecules, none approved. Second, price to book of roughly nine times: against $198.7 million of stockholders' equity, the market is paying nine dollars for every dollar of accounting substance. For a company whose only real asset is intellectual property that accounting rules force it to expense rather than capitalize, that multiple is less absurd than it looks — but it is the honest measure of how much of this price is expectation. A useful yardstick from the company's own filing: on June 30, 2025, the market value of the stock held by non-affiliates was about $361.3 million. The valuation has multiplied several times over in a year, on trial data and an FDA meeting rather than a single dollar of product revenue. The professionals are unanimous, for whatever unanimity is worth in this corner of the market: seven analysts cover the stock — five strong buy, two buy, no holds and no sells — with an average price target around $14 (data as of July 16, 2026), roughly triple the recent price. Read that with the same suspicion you would apply to any chorus: analyst coverage of clinical-stage biotech is written by specialists who like the science, and a target three times the price is a statement about a binary outcome, not a valuation. Roughly 44 percent of the stock sits with institutions, insiders hold about 2.4 percent, and short interest is negligible at about 0.1 percent of the float — nobody is betting hard against this, and nobody has to: the trials will settle it.

Opportunities and risks at a glance

What speaks for AtaiBeckley:

• A real and enormous unmet need: roughly 65 percent of depression patients reach no remission after up to four antidepressant trials, and about half of the estimated 300 million people with depression worldwide are considered treatment-resistant (annual report 10-K for 2025, Item 1).
• Early data with a genuinely unusual profile: in Part 1 of the BPL-003 Phase 2a study, a single 10 mg dose produced a response in 55 percent of patients the day after dosing, still holding at weeks 4 and 12, with patients generally discharge-ready in under two hours and no serious adverse events reported; Part 2 showed an 18-point mean drop on the depression scale still present at three months.
• The regulator is engaged: after an End-of-Phase 2 meeting with the FDA in February 2026, the company said it was on track to start the Phase 3 program — two pivotal trials with 52-week extensions — in the second quarter of 2026.
• No going-concern doubt and no debt overhang: $209.9 million of cash and short-term securities as of March 31, 2026, the old Hercules term loan repaid and terminated in May 2025, and management's estimate that the money funds operations into 2029.
• Four shots, not one: BPL-003 (nasal spray, treatment-resistant depression), VLS-01 (buccal film), EMP-01 (social anxiety) and a discovery program aimed at non-hallucinogenic molecules — plus $20.9 million in COMPASS Pathways shares as a non-dilutive reserve (10-Q as of March 31, 2026). Seven analysts cover the stock, all positive, with an average target around $14 (data as of July 16, 2026).

What speaks against it:

• No approved product and no product revenue at all: 2025's $4.1 million of revenue came from licensing and the Nualtis research-services subsidiary, not the pipeline; the accumulated deficit reached $1.4 billion (March 31, 2026), and the annual report states the company has "no products that are approved for commercial sale".
• Dilution is the business model of the balance sheet: the share count more than doubled from 168.0 million to 363.3 million during 2025 and reached 368.2 million by May 8, 2026; four raises brought in $269.5 million; the 10-K concedes "our shareholders experienced significant dilution"; a fresh at-the-market program was armed on March 6, 2026, with 750.0 million shares authorized.
• The runway arithmetic is tight: $209.9 million against a 2025 burn of $102.7 million and a first-quarter 2026 expense run rate annualizing to about $127 million — while two Phase 3 trials, the most expensive undertaking in the company's history, are only beginning.
• Even success needs a second regulator: 5-MeO-DMT sits in Schedule I, and the annual report warns "There can be no assurance that the DEA will make a favorable scheduling decision" — after which state-level scheduling, DEA registrations, quotas and security requirements all follow as permanent cost.
• Nothing to lean on but the documents: ATAI has no row in our company universe and therefore no Piotroski score, no Altman Z and no scanner grade; the outcome is binary, resting on small studies (12 patients dosed per part in the Phase 2a) and a trial calendar that has slipped before — the report itself notes that BPL-003 alcohol-use-disorder results expected in 2024 arrived in January 2025.

A human conclusion

Back to set and setting. Three findings, and each one changes depending on the room you read it in. Finding one: the frightening number is the least frightening thing here. The $660 million loss is 80 percent a bookkeeping entry for research bought with shares; the company burned $102.7 million, and it holds $209.9 million. Anyone who sells on that headline is reacting to the lighting. Finding two: the comforting number deserves more suspicion than the frightening one. "Funded into 2029" is not a lie, but it is a division whose denominator is heading the wrong way — a $127 million annualized run rate against an implied $75 to $80 million, in the years two pivotal trials start. Nothing about that is a crisis; everything about it is a reason to read the next few cash-flow statements rather than the next few press releases. Finding three: the thing that decides this stock is not in any of these numbers. It is whether a nasal spray of 5-MeO-DMT halves depression scores in several hundred patients rather than twelve — and then whether the DEA unlocks the cabinet. Between here and there sit two Phase 3 trials, 52-week extensions, a scheduling process and, on the evidence of the last twelve months, more shares than exist today. That is not a criticism of the company. It is a description of what a clinical-stage biotech is: an option on a molecule, funded by your ownership percentage, priced at $1.83 billion by people who cannot know the answer either. Whether that option is worth its premium to you depends on something no filing can tell you — how you feel about a bet where the middle outcomes barely exist. What you make of it is your decision. And that is exactly as it should be.

Sources

All original documents used in this analysis — to read for yourself:

• AtaiBeckley Inc. — SEC annual report 10-K for 2025 (filed March 6, 2026)
• AtaiBeckley Inc. — SEC quarterly report 10-Q as of March 31, 2026 (filed May 12, 2026)
• AtaiBeckley Inc. — SEC current report 8-K of March 6, 2026 (Open Market Sale Agreement with Jefferies, the at-the-market program)
• AtaiBeckley Inc.'s complete SEC filing history (CIK 0002081043): EDGAR overview (sec.gov)
• Predecessor Atai Beckley N.V. / ATAI Life Sciences N.V. (CIK 0001840904), including the Form 15-12G deregistration of December 31, 2025: EDGAR overview (sec.gov)
• Fundamental data (metrics, quarterly series, valuation, analyst estimates; data as of July 16, 2026), reconciled with the SEC filings.
• Reddit mentions: ApeWisdom (12 mentions in 24 hours, as of July 16, 2026); our in-house stock scanner carries no row for this ticker.

Transparency & disclaimer: This analysis is a journalistic contextualization of publicly available information and is not investment advice, not a financial analysis in the regulatory sense, and not a solicitation to buy or sell securities. Stock investments carry substantial risks up to total loss — with clinical-stage biotechnology, the total loss of the invested capital is a realistic scenario. All information without guarantee; the data cut-off is noted in the text in each case. The author holds no position in AtaiBeckley stock at the time of publication.